Cemiplimab (Regeneron/Sanofi) Drug Overview 2017-2026: A Programmed Death-1 (PD-1)-Targeted Monoclonal Antibody - ResearchAndMarkets.com

DUBLIN--()--The "Cemiplimab" report has been added to ResearchAndMarkets.com's offering.

Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting in tumor cell survival and proliferation due to immune system suppression. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.

Key Topics Covered

  1. Drug Overview
  2. Product Profiles
  3. Cemiplimab: Non-small cell lung cancer (NSCLC)

List of Figures

Figure 1: The authors drug assessment summary for Tagrisso in non-small cell lung cancer

Figure 2: The authors drug assessment summary for Imfinzi in non-small cell lung cancer

List of Tables

Table 1: Cemiplimab drug profile

Table 2: Cemiplimab Phase III trials in non-small cell lung cancer

Table 3: Cemiplimab early-phase data in non-small cell lung cancer

Table 4: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 5: Cemiplimab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

Table 6: Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/k046tk

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs